IGF1 and neoplasm: To overcome blocking that action without interfering the insulin axis insulin receptor activation, BI836845 (Xentuzumab), a drug that targets both IGF‐1 and IGF‐2, was developed and there are many ongoing clinical trials on various type of tumour.20